Show simple item record

dc.contributor.authorSchiffer, Celia A.
dc.date2022-08-11T08:08:00.000
dc.date.accessioned2022-08-23T15:39:04Z
dc.date.available2022-08-23T15:39:04Z
dc.date.issued2013-07-01
dc.date.submitted2015-01-09
dc.identifier.citationFuture Med Chem. 2013 Jul;5(11):1193-7. doi: 10.4155/fmc.13.106. <a href="http://dx.doi.org/10.4155/fmc.13.106">Link to article on publisher's site</a>
dc.identifier.issn1756-8919 (Linking)
dc.identifier.doi10.4155/fmc.13.106
dc.identifier.pmid23859201
dc.identifier.urihttp://hdl.handle.net/20.500.14038/26077
dc.description.abstractCelia Schiffer, a Professor in Biochemistry and Molecular Pharmacology; a former Director of UMass Center for AIDS Research; and a Founder and Co-Director for the Institute for Drug Resistance (University of Massachusetts Medical School, MA, USA). Schiffer has an undergraduate degree in physics from the University of Chicago, with a PhD in biophysics from University of California, San Francisco (CA, USA). She was a postdoctoral associate first at the ETH in Zurich and then at Genentech in San Francisco. Schiffer has published more than 100 peer reviewed journal articles. Her laboratory primarily uses structural biology, biophysical and chemistry techniques to study the molecular basis for drug resistance in anti-virals including: HIV, Hepatitis C, Influenza and Dengue. Her laboratory designs, synthesizes and tests new antiviral inhibitors that should be more robust to resistance. She has overseen more than US$30 million in research funding. She is also an outstanding mentor and educator, receiving a faculty mentoring award, a highly sought after PhD advisor. Interview conducted by Hannah Coaker, Assistant Commissioning Editor.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23859201&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.4155/fmc.13.106
dc.subjectAntiviral Agents
dc.subjectDrug Design
dc.subject*Drug Resistance, Viral
dc.subjectHIV
dc.subjectHIV Infections
dc.subjectHIV Protease
dc.subjectHIV Protease Inhibitors
dc.subjectHepacivirus
dc.subjectHepatitis C
dc.subjectHumans
dc.subject*Research
dc.subjectBiochemistry
dc.subjectChemicals and Drugs
dc.subjectMicrobiology
dc.subjectMolecular Biology
dc.subjectTherapeutics
dc.subjectVirus Diseases
dc.titleInterview with Celia Schiffer
dc.typeJournal Article
dc.source.journaltitleFuture medicinal chemistry
dc.source.volume5
dc.source.issue11
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/bmp_pp/214
dc.identifier.contextkey6515363
html.description.abstract<p>Celia Schiffer, a Professor in Biochemistry and Molecular Pharmacology; a former Director of UMass Center for AIDS Research; and a Founder and Co-Director for the Institute for Drug Resistance (University of Massachusetts Medical School, MA, USA). Schiffer has an undergraduate degree in physics from the University of Chicago, with a PhD in biophysics from University of California, San Francisco (CA, USA). She was a postdoctoral associate first at the ETH in Zurich and then at Genentech in San Francisco. Schiffer has published more than 100 peer reviewed journal articles. Her laboratory primarily uses structural biology, biophysical and chemistry techniques to study the molecular basis for drug resistance in anti-virals including: HIV, Hepatitis C, Influenza and Dengue. Her laboratory designs, synthesizes and tests new antiviral inhibitors that should be more robust to resistance. She has overseen more than US$30 million in research funding. She is also an outstanding mentor and educator, receiving a faculty mentoring award, a highly sought after PhD advisor.</p> <p>Interview conducted by Hannah Coaker, Assistant Commissioning Editor.</p>
dc.identifier.submissionpathbmp_pp/214
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages1193-7


This item appears in the following Collection(s)

Show simple item record